This article was originally published in The Gray Sheet
U.S. shipments of the coronary stent for treatment of free perforations in native coronary vessels or saphenous vein bypass grafts are expected to commence in the second quarter following FDA humanitarian device exemption approval Jan. 10. The device will be marketed by the Swiss firm's 50-rep U.S. sales force. The market for the $2,200 stent is estimated at 3,000-4,000 units annually
You may also be interested in...
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.
As the US heads into a COVID-19 storm with grave concerns about the lack of face masks and respirators for health care workers, the FDA has further relaxed federal oversight for such products, giving more responsibility to employers
FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.